LGND Ligand Pharmaceuticals Incorporated

NASDAQ
$284.47

Ligand Pharmaceuticals Incorporated (LGND) Insider Activity

What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.

30D 90D 6M 1Y
Insider signal In line Selling ran in line with LGND's own trailing one-year pace, with 64% of sale value under a prearranged plan.
Cluster activity 0 buyers in the last 30 days 0 buyers in the last 90 days 4 sellers in the last 90 days
Insiders buying
0
0 transactions
Insiders selling
8
131 transactions
Purchases
$0
0 shares
Sales
$34.7M
141,975 shares
Net activity
-$34.7M
purchases less sales

How much of that selling was preplanned? 64% planned / 36% discretionary

10b5-1 plan sales $22.2M 108 transactions · 86,857 shares
Discretionary sales $12.5M 23 transactions · 55,118 shares

Largest single sale: $9.2M.

Where they traded

Buy Sell Dot area is proportional to transaction value.

No open-market insider purchase on record.

Recent open-market activity

Date Insider Role Action Shares Price Value Held after
Reardon Andrew 5 fills CLO & Secretary Sell 10b5-1 5,000 $286.09 $1.4M 41,214 −10.8% of holding
Espinoza Octavio Chief Financial Officer Sell 10b5-1 31,641 $292.06 $9.2M 27,696 −53.3% of holding
Haas Jason Director Sell 7,138 $292.81 $2.1M 3,981 −64.2% of holding
Reardon Andrew 10 fills CLO & Secretary Sell 10b5-1 5,000 $288.99 $1.4M 46,409 −9.7% of holding
Reardon Andrew 8 fills CLO & Secretary Sell 10b5-1 5,000 $313.28 $1.6M 46,118 −9.8% of holding
Sabba Stephen L Director Sell 2,145 $254.00 $544.8K 33,629 −6% of holding
Haas Jason 2 fills Director Sell 6,461 $255.58 $1.7M 8,442 −43.4% of holding
Aryeh Jason Director Sell 4,500 $250.00 $1.1M 102,580 −4.2% of holding
LAMATTINA JOHN L 4 fills Director Sell 4,591 $250.88 $1.2M 31,303 −12.8% of holding
Aryeh Jason Director Sell 500 $250.00 $125.0K 107,080 −0.5% of holding
Reardon Andrew 7 fills CLO & Secretary Sell 10b5-1 5,000 $227.06 $1.1M 45,891 −9.8% of holding
KOZARICH JOHN W Director Sell 1,575 $223.50 $352.0K 41,786 −3.6% of holding
KOZARICH JOHN W Director Sell 459 $224.00 $102.8K 41,786 −1.1% of holding
Reardon Andrew 7 fills CLO & Secretary Sell 10b5-1 5,000 $231.31 $1.2M 45,782 −9.8% of holding
KOZARICH JOHN W 5 fills Director Sell 10b5-1 467 $231.80 $108.3K 42,173 −1.1% of holding
Reardon Andrew 6 fills CLO & Secretary Sell 10b5-1 5,000 $201.24 $1.0M 45,922 −9.8% of holding
KOZARICH JOHN W 5 fills Director Sell 10b5-1 467 $202.23 $94.4K 42,574 −1.1% of holding
Sabba Stephen L Director Sell 1,000 $207.87 $207.9K 32,793 −3% of holding
Espinoza Octavio Chief Financial Officer Sell 10b5-1 3,057 $225.00 $687.8K 21,010 −12.7% of holding
LAMATTINA JOHN L Director Sell 2,161 $200.76 $433.8K 30,724 −6.6% of holding
Espinoza Octavio 11 fills Chief Financial Officer Sell 10b5-1 13,423 $205.83 $2.8M 34,386 −28.1% of holding
Reardon Andrew 11 fills CLO & Secretary Sell 10b5-1 5,000 $206.35 $1.0M 41,769 −10.7% of holding
Sabba Stephen L Director Sell 2,034 $201.50 $409.9K 33,793 −5.7% of holding
KOZARICH JOHN W 6 fills Director Sell 10b5-1 467 $200.50 $93.6K 43,140 −1.1% of holding
KOZARICH JOHN W 5 fills Director Sell 10b5-1 467 $195.91 $91.5K 43,615 −1.1% of holding
KOZARICH JOHN W 5 fills Director Sell 10b5-1 467 $189.58 $88.5K 44,100 −1% of holding
Espinoza Octavio Chief Financial Officer Sell 1,804 $188.31 $339.7K 26,186 −6.4% of holding
KOZARICH JOHN W 7 fills Director Sell 10b5-1 467 $195.84 $91.5K 44,496 −1% of holding
Gray Nancy Ryan 2 fills Director Sell 6,571 $205.45 $1.4M 8,094 −44.8% of holding
LAMATTINA JOHN L 2 fills Director Sell 4,179 $205.45 $858.6K 30,724 −12% of holding
KOZARICH JOHN W 4 fills Director Sell 10b5-1 467 $191.05 $89.2K 44,971 −1% of holding
KOZARICH JOHN W 4 fills Director Sell 10b5-1 467 $179.44 $83.8K 45,498 −1% of holding
Aryeh Jason 3 fills Director Sell 10,000 $170.81 $1.7M 74,871 −11.8% of holding

Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.